Abstract
Background. In Ukraine the problem of chronic obstructive pulmonary disease (COPD) is extremely pointed. In particular, over the last decade, the incidence rate of COPD (before 2004 - chronic obstructive bronchitis) has increased by 6.9%, while the proportion among newly diagnosed diseases was about 38.0%
Aim. The purpose of this study was to investigate the effects of 500 μg roflumilast, taken once daily for 180 days on pulmonary function tests on abase of COPD treatment according to GOLD.
Materials and methods. Spirometry is the best way of detecting the presence of airway obstruction and it was perfomed using "Spirocom" (Kharkov, Ukraine) in 151 patients before and at 180 day of treatment with roflumilast.
Results. Compared with the group of patients, who did not use roflumilast, FEV1 consistently increased in 1.28 times (p< 0.05), FVC in 1.05 times (p>0.05), FEV1/FVC in 1.21 times.
Conclusions. Roflumilast was associated with significant improvements in lung function in patients with severe COPD after 180 days of treatment.
- © 2013 ERS